In Brief

EWG slams FDA sunscreen oversight; NARB stays the course in Healthy Directions case; AHPA presses FDA on NDI ID guidance; CRN comments on “chemically altered” NDIs; and Desert Rose products lack full labels.

The U.S. market still lags behind Europe when it comes to safe and effective sunscreen products, the Environmental Working Group maintains in its annual Sunscreen Guide rating more than 1,400 products. Summer 2013 is the first summer after manufacturers were required to comply with an FDA rule requiring sunscreen products to feature an SPF 15 or higher and meet criteria for broad-spectrum protection to claim they reduce the risk of skin cancer or early skin aging caused by sun exposure Also see "FDA Strengthens Sunscreen Testing And Label Requirements" - Pink Sheet, 20 June, 2011.. EWG maintains FDA’s standards are not high enough. Just 25% of sunscreen products reviewed passed muster with the group, which cited products for containing oxybenzone and/or retinyl palmitate, both linked to adverse health effects. EWG also takes issue with sunscreen sprays and products with SPFs above 50. FDA released a proposed rule in June 2011 to cap sunscreens at 50+, as well as an advanced notice of proposed rulemaking asking firms to submit safety and efficacy data for spray sunscreens, lest they be excluded from the final monograph (Also see "FDA Considers Capping SPF Values At 50+ Despite Efficacy Data" - Pink Sheet, 20 June, 2011. and Also see "FDA Questions Spray Sunscreen Safety, Efficacy And Monograph Status" - Pink Sheet, 27 June, 2011.).

The National Advertising Review Board recommends Healthy Directions LLC discontinue several claims for Joint Advantage Gold, including that thesupplement product’s...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Marketing & Advertising

‘Sex Pill For Women’: Sprout CEO’s Addyi Instagram Post Draws US FDA Warning Letter

 
• By 

Cindy Eckert’s social media post with a People.com story failed to include any risk information, made misleading representations about benefits and omitted material information about the indication, said the agency, which flagged similar concerns about an Addyi radio ad five years ago.

Novo, Lilly Ad Challenges Cause Discontinued Claims For Compounded GLP-1s

 
• By 

Two pharmacies, a medical spa and a telehealth company voluntarily removed efficacy, safety and quality claims for compounded GLP-1 products after innovator companies filed challenges with the National Advertising Division.

Pharma DTC Ad Tax Break Targeted By US HHS, Congress

 

Health and Human Services Secretary Robert F. Kennedy Jr. said a policy that would remove the tax write-off for pharma advertising expenses would be coming in a few weeks.

Sarfez Pharma’s Promotional Claims For Diuretic Soaanz Draw US FDA Warning Letter

 
• By 

Webpages, a healthcare professional pamphlet and a medical conference exhibit booth panel make unsupported comparative superiority claims about generic torsemide products and misrepresent risks, the Office of Prescription Drug Promotion says in its first warning letter of 2025.

More from Compliance

UK MHRA: Bacteriophage Developers Wanted ‘More Clarity’ On UK Framework

 

Julian Beach, interim executive director of healthcare quality and access at the UK drug regulator, the MHRA, tells the Pink Sheet how the agency is responding to increased efforts to develop bacteriophage therapies.

Novo, Lilly Ad Challenges Cause Discontinued Claims For Compounded GLP-1s

 
• By 

Two pharmacies, a medical spa and a telehealth company voluntarily removed efficacy, safety and quality claims for compounded GLP-1 products after innovator companies filed challenges with the National Advertising Division.

EU Emergency Response Authority Needs Bigger Budget To Address Health Threats, Says Industry

 

The EU must renew the mandate of its Health Emergency Response Authority to support medicine stockpiles and enable agile manufacturing to combat antimicrobial resistance and chemical, biological, radiological and nuclear threats, says trade organization EUCOPE.